<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05021198</url>
  </required_header>
  <id_info>
    <org_study_id>NoCVT</org_study_id>
    <nct_id>NCT05021198</nct_id>
  </id_info>
  <brief_title>The Norwegian Cerebral Venous Thrombosis Study</brief_title>
  <acronym>NoCVT</acronym>
  <official_title>Epidemiology, Clinical and Radiological Presentation and Long-term Prognosis of Cerebral Venous Thrombosis in a Norwegian Population (NoCVT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Akershus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Drammen sykehus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sorlandet Hospital HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nordlandssykehuset HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital of North Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oslo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital de Santa Maria, Portugal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Akershus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The NoCVT study will investigate CVT (2010-2019) in a large Norwegian population (&gt; 3&#xD;
      millions) using several approaches combining existing health registries, clinical databases&#xD;
      and new prospectively collected clinical data to explore epidemiology, risk factors,&#xD;
      diagnostics, treatment, and the long-term prognosis of CVT.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A retrospective hospital-based chart review will be conducted at eight different hospitals&#xD;
      covering all four health regions and more than 3 million inhabitants in Norway. These eight&#xD;
      hospitals are Akershus University Hospital, Haukeland University Hospital. Oslo University&#xD;
      Hospital (Ullevål), Sørlandet Hospital Kristiansand, Drammen Hospital, St.Olavs Hospital,&#xD;
      Nordlandsykehuset Bodø, University Hospital of North Norway.&#xD;
&#xD;
      A search will be made in the clinical database for patients with the relevant diagnosis of&#xD;
      CVT in the period between January 1, 2010, and December 31, 2019. Data from hospital charts&#xD;
      will be linked with data from Statistics Norway (SSB), FD-Trygd, and Norwegian Prescription&#xD;
      Database (NorPD). Using this combination of clinical data and health registries will make it&#xD;
      possible to describe risk factors, clinical and radiological presentation, treatment and&#xD;
      short-term outcome in a large Norwegian CVT cohort.&#xD;
&#xD;
      Further, data from hospitals will be linked with data from SSB, FD-Trygd, NorPD, Norwegian&#xD;
      Patient Registry (NPR) and Cause of Death Registry (DÅR) up to five years after CVT. Using&#xD;
      this methodology will make it possible to investigate overall long-term prognosis and&#xD;
      outcomes in terms of mortality, health care utilisation, medication use and working situation&#xD;
      up to five years after CVT in a large Norwegian cohort.&#xD;
&#xD;
      Lastly, a prospective follow-up study will include patients that have been diagnosed with CVT&#xD;
      at the NoCVT hospitals during 2015-2019. By combining the collected data from the&#xD;
      retrospective hospital chart review with the new follow-up interviews and self-reported&#xD;
      questionnaires it will be possible to describe quality of life, vocational outcomes,&#xD;
      psychological distress, depression, insomnia and disease-related disability in CVT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2010</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality of CVT in a Norwegian population</measure>
    <time_frame>Baseline, 3 months, 12 months, 24 months and 5 years</time_frame>
    <description>Number dead vs total number of cases</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Health care utilisation after CVT</measure>
    <time_frame>Baseline to five years</time_frame>
    <description>Number of new health care system contacts among CVT cases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-admission after CVT</measure>
    <time_frame>Baseline to five years</time_frame>
    <description>Number of new re-admission among CVT cases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New diagnosis after CVT</measure>
    <time_frame>Baseline to five years</time_frame>
    <description>Type of new diagnosis among CVT cases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New prescriptions after CVT</measure>
    <time_frame>Baseline to five years</time_frame>
    <description>Type of new prescriptions among CVT cases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nursing home after CVT</measure>
    <time_frame>Baseline to five years</time_frame>
    <description>Number of CVT cases in need for nursing home</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of anti-coagulation in the long-term after CVT</measure>
    <time_frame>Baseline to five years</time_frame>
    <description>Number of cases with CVT using anti-coagulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of anti-platelet therapy in the long-term after CVT</measure>
    <time_frame>Baseline to five years</time_frame>
    <description>Number of cases with CVT using anti-platelet therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of painkillers in the long-term after CVT</measure>
    <time_frame>Baseline to five years</time_frame>
    <description>Number of cases with CVT using painkillers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of headache prophylactics in the long-term after CVT</measure>
    <time_frame>Baseline to five years</time_frame>
    <description>Number of cases with CVT using headache prophylactics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of anti-epileptic drugs in the long-term after CVT</measure>
    <time_frame>Baseline to five years</time_frame>
    <description>Number of cases with CVT using anti-epileptic drugs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of anti-depressants in the long-term after CVT</measure>
    <time_frame>Baseline to five years</time_frame>
    <description>Number of cases with CVT using anti-epileptic drugs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sick-leave after CVT</measure>
    <time_frame>Baseline to five years</time_frame>
    <description>Number of cases with CVT on sick-leave</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disability pension after CVT</measure>
    <time_frame>Baseline to five years</time_frame>
    <description>Number of cases with CVT on disability pension</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Headache after CVT</measure>
    <time_frame>Baseline to five years</time_frame>
    <description>Type and frequency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Headache-related quality of life after CVT</measure>
    <time_frame>Baseline to five years</time_frame>
    <description>Migraine Disability Assessment Score and Headache Impact Test-6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seizure/epilepsy after CVT</measure>
    <time_frame>Baseline to five years</time_frame>
    <description>Type and frequency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epilepsy-related quality of life after CVT</measure>
    <time_frame>Baseline to five years</time_frame>
    <description>Quality of Life in Epilepsy Inventory-31</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life after CVT</measure>
    <time_frame>Baseline to five years</time_frame>
    <description>EuroQoL 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychological distress after CVT</measure>
    <time_frame>Baseline to five years</time_frame>
    <description>Patient Health Questionnaire-9 and Hospital Anxiety and Depression Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep problems after CVT</measure>
    <time_frame>Baseline to five years</time_frame>
    <description>Bergen Insomnia Scale</description>
  </secondary_outcome>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Cerebral Vein Thrombosis</condition>
  <condition>Cerebral Venous Sinus Thrombosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        A retrospective hospital-based chart review will be conducted at eight different hospitals&#xD;
        covering approximately 3 million inhabitants in Norway.&#xD;
&#xD;
        More precis, a validated ICD-10 search will be made in the clinical database for patients&#xD;
        with the diagnosis of CVT in the period between January 1, 2010, and December 31, 2019.&#xD;
        Data from the clinical databases at these hospitals will be linked with the mandatory&#xD;
        National Health Registries for baseline data and prospectively collected follow-up data.&#xD;
        The National Health Registries involved are Statistics Norway (SSB), Norwegian Prescription&#xD;
        Database (NorPD), Norwegian Patient Registry (NPR) and Cause of Death Registry (DÅR).&#xD;
&#xD;
        In addition a clinical follow-up interview will be conducted with emphasis on long-term&#xD;
        outcomes.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A diagnosis of CVT 2010-2019 from the eight participating primary hospitals&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  none&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Espen Saxhaug Kristoffersen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Akershus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Espen Saxhaug Kristoffersen, MD, PhD</last_name>
    <email>e.s.kristoffersen@medisin.uio.no</email>
  </overall_contact>
  <location>
    <facility>
      <name>Akershus University Hospital</name>
      <address>
        <city>Lørenskog</city>
        <zip>1478</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Espen Saxhaug Kristoffersen, MD, PhD</last_name>
      <email>e.s.kristoffersen@medisin.uio.no</email>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 27, 2021</study_first_submitted>
  <study_first_submitted_qc>August 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2021</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Akershus</investigator_affiliation>
    <investigator_full_name>Espen Saxhaug Kristoffersen</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sinus Thrombosis, Intracranial</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

